ClinicalTrials.gg
CompletedNCT05440344Updated Nov 12, 2025Results posted

A Study of Imlunestrant (LY3484356) in Female Participants With Impaired Liver Function

A Phase 1 interventional study of Imlunestrant in Hepatic Insufficiency and Healthy, sponsored by Eli Lilly and Company. Completed at 3 sites in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-12.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
27
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Hepatic Insufficiency by Eli Lilly and Company — 2 open to participants now, 2 under way, none of them phase 3. Hepatic Insufficiency · Eli Lilly and Company.

Enrollment
11th of 12
27 · median 34
Started
2022
the only one that year
Phase 1
12 of 12
2 open now
Registered
6th of 12
by date

Among the 12 studies in Hepatic Insufficiency by Eli Lilly and Company, this one is the 11th largest by enrollment, is the only one that started in 2022, is one of 12 in phase 1, and was the 6th registered.

Hepatic Insufficiency

113 studies on the registry are indexed under Hepatic Insufficiency; 15 are open to participants now.

Browse Hepatic Insufficiency studies →

Open to participants now

2 of the 12 studies in Hepatic Insufficiency by Eli Lilly and Company are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 9 Hepatic Insufficiency studies recruiting now, 3 set no upper age limit and 3 stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.

This study: 18 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Hepatic Insufficiency by Eli Lilly and Company, or all of them as a file.
02

Study summary

The main purpose of this study is to measure how much of Imlunestrant (LY3484356) gets into the bloodstream and how long it takes the body to eliminate it in female participants with impaired liver function compared to female participants with normal liver function. The side effects and tolerability of Imlunestrant will also be evaluated. The study may last up to 46 days for each participant.

03

Conditions studied

  • Hepatic Insufficiency
  • Healthy

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All Participants:

  • Women not of may participate and include those who are infertile due to surgical sterilization (hysterectomy, bilateral oophorectomy, bilateral salpingectomy or tubal ligation), congenital anomaly such as mullerian agenesis; or
  • Are between the (BMI) of 18.0 and 42.0 kilograms per meter squared (kg/m²), inclusive, at screening

Healthy Participants:

- Healthy females as determined by medical history, physical examination, and other screening procedures, with normal liver function

Participants with Impaired Liver Function:

  • Females with chronic mild, moderate and severe liver impairment, assessed by scoring
  • Have diagnosis of chronic hepatic impairment (>6 months), with no changes within 90 days prior to study drug administration.

Exclusion criteria

Exclusion Criteria:

  • Women of are excluded from the study.
  • Have known allergies to imlunestrant or related compounds
  • Have a history of alcoholism or drug/chemical abuse within 2 years prior to check-in
  • Have received blood products within 2 months prior to check-in
  • Have evidence of infection and/or positive human HIV antibodies
  • Have used or intend to use medications that are strong inhibiters or inducers of cytochrome P450 (CYP)3A4
  • Who smoke more than 10 cigarettes or use the equivalent tobacco, smoking-cessation products, nicotine-containing products, or e-cigarettes (nicotine and non-nicotine) per day.
  • Have a history or presence of cardiovascular (eg, symptomatic bradycardia with resting heart rate of \<60 beats per minute), respiratory, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    Imlunestrant (Normal Hepatic Function)

    Participants received a single dose of Imlunestrant 400 milligrams (mg) administered orally on Day 1 in fasted state.

    Drug: Imlunestrant

  • Experimental
    Imlunestrant (Mild Hepatic Impairment)

    Participants received a single dose of Imlunestrant 400 mg administered orally on Day 1 in fasted state.

    Drug: Imlunestrant

  • Experimental
    Imlunestrant (Moderate Hepatic Impairment)

    Participants received a single dose of Imlunestrant 400 mg administered orally on Day 1 in fasted state.

    Drug: Imlunestrant

  • Experimental
    Imlunestrant (Severe Hepatic Impairment)

    Participants received a single dose of Imlunestrant 200 mg administered orally on Day 1 in fasted state.

    Drug: Imlunestrant

Interventions

  • Administered orally.

    Also known as: LY3484356

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Imlunestrant

    PK: Cmax of Imlunestrant is reported.

    Time frame: Day 1 (Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, 240 hours post dose)

  2. PK: Area Under the Concentration-time Curve From 0 to the Last Measurable Concentration (AUC[0-t]) of Imlunestrant

    AUC(0-t) of Imlunestrant is reported.

    Time frame: Day 1 (Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, 240 hours post dose)

07

Results

Posted Nov 12, 2025

Participant flow

Participant flow — Overall Study
MilestoneImlunestrant (Normal Hepatic Function)Imlunestrant (Mild Hepatic Impairment)Imlunestrant (Moderate Hepatic Impairment)Imlunestrant (Severe Hepatic Impairment)
Started9666
Received at least one dose of study drug9666
Completed9666
Not completed0000

Outcome measures

PrimaryPharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Imlunestrant

PK: Cmax of Imlunestrant is reported.

Time frame:
Day 1 (Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, 240 hours post dose)
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Imlunestrant
nanograms per milliliter (ng/mL)Imlunestrant (Normal Hepatic Function)Imlunestrant (Mild Hepatic Impairment)Imlunestrant (Moderate Hepatic Impairment)Imlunestrant (Severe Hepatic Impairment)
Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Imlunestrant58.0 ± 5674.9 ± 4787.6 ± 5146.2 ± 49
PrimaryPK: Area Under the Concentration-time Curve From 0 to the Last Measurable Concentration (AUC[0-t]) of Imlunestrant

AUC(0-t) of Imlunestrant is reported.

Time frame:
Day 1 (Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, 240 hours post dose)
Reported as:
Geometric mean · nanograms*hour per milliliter (ng*h/mL)
PK: Area Under the Concentration-time Curve From 0 to the Last Measurable Concentration (AUC[0-t]) of Imlunestrant
nanograms*hour per milliliter (ng*h/mL)Imlunestrant (Normal Hepatic Function)Imlunestrant (Mild Hepatic Impairment)Imlunestrant (Moderate Hepatic Impairment)Imlunestrant (Severe Hepatic Impairment)
PK: Area Under the Concentration-time Curve From 0 to the Last Measurable Concentration (AUC[0-t]) of Imlunestrant1970 ± 512410 ± 274320 ± 502820 ± 47

Adverse events

Collected over Baseline up to 18 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Imlunestrant (Normal Hepatic Function)0/9 (0%)0/9 (0%)0/9 (0%)
Imlunestrant (Mild Hepatic Impairment)0/6 (0%)0/6 (0%)0/6 (0%)
Imlunestrant (Moderate Hepatic Impairment)0/6 (0%)1/6 (16.7%)2/6 (33.3%)
Imlunestrant (Severe Hepatic Impairment)0/6 (0%)0/6 (0%)2/6 (33.3%)
Most frequent serious events
Most frequent serious events
EventImlunestrant (Normal Hepatic Function)Imlunestrant (Mild Hepatic Impairment)Imlunestrant (Moderate Hepatic Impairment)Imlunestrant (Severe Hepatic Impairment)
Portal vein thrombosisHepatobiliary disorders0/90/61/60/6
Most frequent other events
Most frequent other events
EventImlunestrant (Normal Hepatic Function)Imlunestrant (Mild Hepatic Impairment)Imlunestrant (Moderate Hepatic Impairment)Imlunestrant (Severe Hepatic Impairment)
NauseaGastrointestinal disorders0/90/62/61/6
Abdominal pain upperGastrointestinal disorders0/90/61/60/6
VomitingGastrointestinal disorders0/90/61/60/6
FallInjury, poisoning and procedural complications0/90/60/61/6
ArthralgiaMusculoskeletal and connective tissue disorders0/90/61/60/6
Back painMusculoskeletal and connective tissue disorders0/90/60/61/6
HeadacheNervous system disorders0/90/61/61/6
InsomniaPsychiatric disorders0/90/61/60/6
PruritusSkin and subcutaneous tissue disorders0/90/61/60/6
RashSkin and subcutaneous tissue disorders0/90/60/61/6

Baseline characteristics

All enrolled participants.

Age, Continuous
Age, Continuous(years)Imlunestrant (Normal Hepatic Function)Imlunestrant (Mild Hepatic Impairment)Imlunestrant (Moderate Hepatic Impairment)Imlunestrant (Severe Hepatic Impairment)Total
Mean60.3 ± 5.066.7 ± 3.159.2 ± 8.357.3 ± 3.160.8 ± 6.0
Sex: Female, Male
Sex: Female, Male(Participants)Imlunestrant (Normal Hepatic Function)Imlunestrant (Mild Hepatic Impairment)Imlunestrant (Moderate Hepatic Impairment)Imlunestrant (Severe Hepatic Impairment)Total
Female966627
Male00000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Imlunestrant (Normal Hepatic Function)Imlunestrant (Mild Hepatic Impairment)Imlunestrant (Moderate Hepatic Impairment)Imlunestrant (Severe Hepatic Impairment)Total
Hispanic or Latino453315
Not Hispanic or Latino513312
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Imlunestrant (Normal Hepatic Function)Imlunestrant (Mild Hepatic Impairment)Imlunestrant (Moderate Hepatic Impairment)Imlunestrant (Severe Hepatic Impairment)Total
American Indian or Alaska Native00101
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American10001
White865625
More than one race00000
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(Participants)Imlunestrant (Normal Hepatic Function)Imlunestrant (Mild Hepatic Impairment)Imlunestrant (Moderate Hepatic Impairment)Imlunestrant (Severe Hepatic Impairment)Total
United States966627
08

Study locations

3 sites
  • Inland Empire Liver Foundation
    Rialto, California 92377, United States
  • Orlando Clinical Research Center
    Orlando, Florida 32809, United States
  • American Research Corporation at Texas Liver Institute
    San Antonio, Texas 78215, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2022 to primary completion in Feb 2024, 19 months.

Results were first posted in Nov 2025, 1 year 8 months after primary completion.

Of 38 industry-sponsored phase 1 interventional studies under Hepatic Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 17. This study's 19 months is above that.

Counting every sponsor, half of 41 studies reached it within 8 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2022
First posted
Jun 30, 2022
StartActual
Jul 5, 2022
Primary completionActual
Feb 28, 2024
CompletionActual
Feb 28, 2024
Results first posted
Nov 12, 2025
Last update
Nov 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05440344
Responsible party
Sponsor
First posted
Jun 30, 2022
Start date
Jul 5, 2022
Primary completion
Feb 28, 2024
Completion
Feb 28, 2024
Results posted
Nov 12, 2025
Last update
Nov 12, 2025

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Imlunestrant

Start the discussion